Business Context and Reporting Period
This Form 8-K is filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) for the reporting period ending June 3, 2019. The registrant is a Delaware corporation with principal executive offices in San Diego, California. The filing reports "Other Events" related to interim clinical study data for two investigational drug candidates.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical trial updates rather than financial performance.
Material Changes and Clinical Updates
- ME-344 Study: On June 1, 2019, the Company reported interim data from an investigator-initiated study of ME-344 in combination with bevacizumab (Avastin) for patients with HER2-negative breast cancer.
- ME-401 Study: On June 3, 2019, the Company reported interim data from its Phase 1b study of ME-401, a selective oral inhibitor of PI3K delta. The study evaluated the drug as a single-agent and in combination with rituximab.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the standard incorporation of press releases by reference. The primary focus is the dissemination of clinical data.
Investor Verification Checklist
- Verify the specific interim data results in the press releases filed as Exhibit 99.1 (June 1, 2019) and Exhibit 99.2 (June 3, 2019).
- Confirm the clinical trial status and next steps for ME-344 and ME-401 based on the reported data.
- Review the Company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K does not contain them.